{
    "nctId": "NCT00897065",
    "briefTitle": "Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17",
    "officialTitle": "Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 957,
    "primaryOutcomeMeasure": "Prognostic utility of the MGH 2-gene and the GHI 21-gene expression signatures",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed primary invasive breast carcinoma resected at time of original diagnosis\n* Treated on clinical trial CAN-NCIC-MA17\n* Hormone receptor status:\n\n  * Estrogen or progesterone receptor positive tumor\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}